You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Long-term Evaluation of AAV-Mediated sFlt-1 Gene Therapy for Ocular Neovascularization in Mice and Monkeys
|
|---|---|
| Published in |
Molecular Therapy, October 2005
|
| DOI | 10.1016/j.ymthe.2005.04.022 |
| Pubmed ID | |
| Authors |
Chooi-May Lai, Wei-Yong Shen, Meliha Brankov, Yvonne K.Y. Lai, Nigel L. Barnett, Shu-Yen Lee, Ian Y.S. Yeo, Ranjana Mathur, Joseph E.S. Ho, Paul Pineda, Amutha Barathi, Chong-Lye Ang, Ian J. Constable, Elizabeth P. Rakoczy |
| Abstract |
Vascular endothelial growth factor (VEGF) is one of the major mediators of retinal ischemia-associated neovascularization. We have shown here that adeno-associated virus (AAV)-mediated expression of sFlt-1, a soluble form of the Flt-1 VEGF receptor, was maintained for up to 8 and 17 months postinjection in mice and in monkeys, respectively. The expression of sFlt-1 was associated with the long-term (8 months) regression of neovascular vessels in 85% of trVEGF029 eyes. In addition, it resulted in the maintenance of retinal morphology, as the majority of the treated trVEGF029 eyes (75%) retained high numbers of photoreceptors, and in retinal function as measured by electroretinography. AAV-mediated expression of sFlt-1 prevented the development of laser photocoagulation-induced choroidal neovascularization in all treated monkey eyes. There were no clinically or histologically detectable signs of toxicity present in either animal model following AAV.sFlt injection. These results suggest that AAV-mediated secretion gene therapy could be considered for treatment of retinal and choroidal neovascularizations. |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| United States | 1 | 2% |
| Netherlands | 1 | 2% |
| Unknown | 62 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 18 | 28% |
| Student > Ph. D. Student | 11 | 17% |
| Student > Bachelor | 5 | 8% |
| Professor | 4 | 6% |
| Student > Postgraduate | 3 | 5% |
| Other | 13 | 20% |
| Unknown | 11 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 25% |
| Biochemistry, Genetics and Molecular Biology | 13 | 20% |
| Agricultural and Biological Sciences | 13 | 20% |
| Engineering | 2 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 4 | 6% |
| Unknown | 15 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2024.
All research outputs
#1,981,233
of 25,374,917 outputs
Outputs from Molecular Therapy
#550
of 4,917 outputs
Outputs of similar age
#3,172
of 70,235 outputs
Outputs of similar age from Molecular Therapy
#2
of 89 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,917 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.2. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 70,235 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 89 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.